samedan logo
 
 
 
spacer
home > ebr > autumn 2002 > editor's letter
PUBLICATIONS
European Biopharmaceutical Review

Editor's Letter

Times are not just tough, they have changed - a stark message but one interpretation of the environment that the European biotechnology sector faces today. As the chillier weather sets in and the hectic autumnal partnering season approaches, it will be interesting to hear whether some of the predictions and sentiments voiced within this issue receive further air time on the partnering conference stage. By volume of companies and people employed, as well as private equity investment, the European sector continues to grow strongly as reflected in DeLoitte & Touche's recently launched annual Mediscience Report, reviewed in this issue. However, the majority of this growth is within established companies, trying to progress technologies towards products and build value and sustainable critical mass 'until' the IPO window opens again. Therein seems to lie perhaps the more fundamental environmental change as institutional investors continue to show less than a glimmer of interest in biotechnology stocks.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Dr Helen Abbott, Senior Consultant at Technomark Consulting Services
spacer
Dr Helen Abbott
spacer
spacer
spacer
Deirdre Ruane
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Schrödinger Announces Acquisition of XTAL BioStructures, Inc.

NEW YORK--(BUSINESS WIRE)--Jan. 18, 2022-- Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the acquisition of XTAL BioStructures, Inc., a private company based in the Greater Boston area that provides structural biology services, including biophysical methods, protein production and purification, and X-ray crystallography, to the pharmaceutical and biotechnology industries.
More info >>

White Papers

Biosimilars In Emerging Markets: Is It A Level Playing Field?

PRA Health Sciences (PRA)

Governments, healthcare payers, and social and health reforms, combined with the increased incidence of conditions such as cancer and diabetes are paving the way for increased uptake of biologic medicines in emerging markets. However, expensive biologic medicines can be prohibitive to many patients, creating a high level of unmet clinical need. At its best, the global expansion of biosimilars can mean a robust and steady supply of existing and new drugs reaching far-flung patient populations, but localized biosimilar drug developments, especially in China and India, combined with a lack of robust pharmacovigilance systems, threaten to derail the industry by putting patient health at risk.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement